340 related articles for article (PubMed ID: 20879880)
21. Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results.
Castel V; Cañete A; Navarro S; García-Miguel P; Melero C; Acha T; Navajas A; Badal MD
Med Pediatr Oncol; 2001 Dec; 37(6):537-42. PubMed ID: 11745893
[TBL] [Abstract][Full Text] [Related]
22. Favorable histology, MYCN-amplified 4S neonatal neuroblastoma.
Chan EL; Harris RE; Emery KH; Gelfand MJ; Collins MH; Gruppo RA
Pediatr Blood Cancer; 2007 Apr; 48(4):479-82. PubMed ID: 16333837
[TBL] [Abstract][Full Text] [Related]
23. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).
Hishiki T; Matsumoto K; Ohira M; Kamijo T; Shichino H; Kuroda T; Yoneda A; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Kaneko T; Hara J; Kaneko M; Ikeda H; Tajiri T; Nakagawara A;
Int J Clin Oncol; 2018 Oct; 23(5):965-973. PubMed ID: 29700636
[TBL] [Abstract][Full Text] [Related]
24. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.
Kohler JA; Rubie H; Castel V; Beiske K; Holmes K; Gambini C; Casale F; Munzer C; Erminio G; Parodi S; Navarro S; Marquez C; Peuchmaur M; Cullinane C; Brock P; Valteau-Couanet D; Garaventa A; Haupt R
Eur J Cancer; 2013 Nov; 49(17):3671-9. PubMed ID: 23907002
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
26. Stage 4S neuroblastoma, a disseminated tumor with excellent outcome.
Elimam NA; Atra AA; Fayea NY; Al-Asaad TG; Khattab TM; Al-Sulami GA; Felimban SK
Saudi Med J; 2006 Nov; 27(11):1734-6. PubMed ID: 17106552
[TBL] [Abstract][Full Text] [Related]
27. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.
Strother DR; London WB; Schmidt ML; Brodeur GM; Shimada H; Thorner P; Collins MH; Tagge E; Adkins S; Reynolds CP; Murray K; Lavey RS; Matthay KK; Castleberry R; Maris JM; Cohn SL
J Clin Oncol; 2012 May; 30(15):1842-8. PubMed ID: 22529259
[TBL] [Abstract][Full Text] [Related]
28. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma.
Kushner BH; Kramer K; Modak S; Qin LX; Yataghena K; Jhanwar SC; Cheung NK
Pediatr Blood Cancer; 2009 Jul; 53(1):17-22. PubMed ID: 19148951
[TBL] [Abstract][Full Text] [Related]
29. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
[TBL] [Abstract][Full Text] [Related]
30. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
Pradhan KR; Johnson CS; Vik TA; Sender LS; Kreissman SG
Pediatr Blood Cancer; 2006 Jun; 46(7):793-802. PubMed ID: 16206215
[TBL] [Abstract][Full Text] [Related]
31. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
32. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
[TBL] [Abstract][Full Text] [Related]
33. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
[TBL] [Abstract][Full Text] [Related]
34. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group.
Donfrancesco A; De Bernardi B; Carli M; Mancini A; Nigro M; De Sio L; Casale F; Bagnulo S; Helson L; Deb G
Eur J Cancer; 1995; 31A(4):612-5. PubMed ID: 7576980
[TBL] [Abstract][Full Text] [Related]
35. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
[TBL] [Abstract][Full Text] [Related]
36. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.
Tweddle DA; Pinkerton CR; Lewis IJ; Ellershaw C; Cole M; Pearson AD
Med Pediatr Oncol; 2001 Jan; 36(1):239-42. PubMed ID: 11464894
[TBL] [Abstract][Full Text] [Related]
37. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
[TBL] [Abstract][Full Text] [Related]
38. Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months.
Kawa K; Ohnuma N; Kaneko M; Yamamoto K; Etoh T; Mugishima H; Ohhira M; Yokoyama J; Bessho F; Honna T; Yoshizawa J; Nakada K; Iwafuchi M; Nozaki T; Mimaya J; Sawada T; Nakamura T; Miyata H; Yamato K; Tsuchida Y
J Clin Oncol; 1999 Oct; 17(10):3216-20. PubMed ID: 10506621
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
40. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents.
West DC; Shamberger RC; Macklis RM; Kozakewich HP; Wayne AS; Kreissman SG; Korf BR; Lavally B; Grier HE
J Clin Oncol; 1993 Jan; 11(1):84-90. PubMed ID: 8418247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
